Market Overview:
Atezolizumab is an anti-PD-L1 antibody used for treatment of various cancer types including lung cancer, bladder cancer and others. It works by blocking the interaction between PD-L1 on cancer cells and its receptor PD-1 on T-cells, thereby helping the immune system to recognize and destroy cancer cells. It provides effective treatment outcomes with minimal side effects compared to chemotherapy and radiations.
Market key trends:
One of the major trends driving the growth of the Atezolizumab market is its increasing adoption in immunotherapy for treatment of non-small cell lung cancer (NSCLC). Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin has gained FDA approval for first line treatment of metastatic non-squamous NSCLC. Studies demonstrate that immunotherapy provided overall survival benefits compared to chemotherapy alone. Increasing diagnosis rates of NSCLC across the world will significantly boost the adoption of immunotherapy and in turn drive the growth of the Atezolizumab market during the forecast period.
The global Atezolizumab Market Share is estimated to be valued at US$ 2.68 Bn in 2023 and is expected to exhibit a CAGR of 16.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Segment Analysis
The global atezolizumab market is segmented based on disease type, end user and region. By disease type, the market is segmented into urothelial carcinoma, lung cancer, head and neck cancer, liver cancer and others. The lung cancer segment dominated the global market in 2022 and is expected to continue its dominance over the forecast period due to high prevalence of lung cancer worldwide.
Key Takeaways
The global atezolizumab market is expected to witness high growth, exhibiting CAGR of 16.% over the forecast period, due to increasing prevalence of cancer worldwide.
Regionally, North America dominated the global market in 2022 and is expected to continue its domination during the forecast period. This is attributed to growing adoption of novel cancer therapies and presence of major market players in the region. Asia Pacific market is expected to exhibit the fastest growth rate over the forecast period owing to rising awareness regarding targeted cancer therapies and improving healthcare infrastructure in emerging countries.
Key players operating in the atezolizumab market are Roche, Novartis, Pfizer, Merck, AstraZeneca, Bristol-Myers Squibb, BeiGene, Innovent Biologics, Genentech, and AbbVie. Roche holds the largest market share owing to its first-to-market PD-L1 inhibitor atezolizumab. Partnerships and new product launches are the key strategies adopted by major players to strengthen their market position.
